Erasca shares plunge 55% after patient death in clinical trial

5 articles · Updated · Bloomberg · Apr 28

A 66-year-old man died after withdrawing from Erasca's trial due to severe lung inflammation linked to the therapy.
The fatality triggered a record drop in Erasca's stock price, intensifying concerns over the safety of its cancer treatment.
Earlier, the company also faced criticism for underwhelming ERAS-0015 data and a patent infringement claim from Revolution Medicines.

With its lead drug faltering, can Erasca survive the onslaught from its rival?

Amid conflicting data, which company is truly winning the cancer drug race?

A patient died after taking the drug. Was it an isolated tragedy or a major red flag?

What makes one experimental drug a 'paradigm shift' while its rival's fails?

Is the trade secret lawsuit a valid IP claim or a tactic to crush a competitor?